EP 3914265 A1 20211201 - B CELL IMMUNOTHERAPY
Title (en)
B CELL IMMUNOTHERAPY
Title (de)
B-ZELL-IMMUNTHERAPIE
Title (fr)
IMMUNOTHÉRAPIE DE LYMPHOCYTES B
Publication
Application
Priority
- US 201962795629 P 20190123
- US 201962837765 P 20190424
- US 2020014836 W 20200123
Abstract (en)
[origin: CN113677354A] The invention, in general, features a method of treating a neurodegenerative disease (such as amyotrophic lateral sclerosis) or a traumatic brain injury in a subject (e.g., a human) in need thereof, the method comprising administering to the subject a therapeutically effective amount of isolated B cells (such as autologous or allogeneic or xenogeneic B cells).
IPC 8 full level
A61K 35/12 (2015.01); A61P 25/28 (2006.01); C12N 5/0781 (2010.01)
CPC (source: EP)
A61K 39/4611 (2023.05); A61K 39/4612 (2023.05); A61K 39/4621 (2023.05); A61K 39/4622 (2023.05); A61K 39/46432 (2023.05); A61K 39/46433 (2023.05); A61P 25/28 (2017.12); A61K 2239/26 (2023.05); A61K 2239/31 (2023.05); A61K 2239/38 (2023.05)
Designated contracting state (EPC)
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
Designated extension state (EPC)
BA ME
DOCDB simple family (publication)
CN 113677354 A 20211119; EP 3914265 A1 20211201; EP 3914265 A4 20230201
DOCDB simple family (application)
CN 202080021588 A 20200123; EP 20745872 A 20200123